Neonatal Lupus Erythematosus (NLE): Comprehensive Research Report

1. Disease Information

Overview: Neonatal lupus erythematosus (NLE) is a rare, passively acquired autoimmune syndrome of the fetus/neonate caused by transplacental transfer of maternal IgG autoantibodies — principally anti-Ro/SSA (anti-Ro52/TRIM21 and anti-Ro60) and often anti-La/SSB, with anti-U1-RNP implicated in a distinct subset. It is explicitly not the neonatal/infant form of systemic lupus erythematosus (SLE); rather, it is "an example of passively acquired autoimmunity in which the influx of maternal autoantibodies... transiently affects fetal and neonatal organ systems" (PMC3437607). The maternal disease may be overt SLE, Sjögren's syndrome, or entirely asymptomatic — many mothers are identified only after their infant's diagnosis.

Key identifiers: - MONDO: MONDO:0018360 - Orphanet: ORPHA:398124 - ICD-10: M32.8 (Other forms of lupus erythematosus); ICD-11: KA07.0 - OMIM: No dedicated OMIM entry exists (NLE is acquired, not Mendelian) - MeSH: Lupus Erythematosus, Systemic (neonatal lupus indexed as a related term)

Synonyms: Neonatal lupus syndrome (NLS); congenital lupus erythematosus; Ro/SSA-associated neonatal lupus.

Evidence base: Predominantly aggregated disease-level data — national/international registries (e.g., the U.S. Research Registry for Neonatal Lupus), multicenter observational cohorts, and systematic literature reviews of individual patient data — rather than single-EHR studies, reflecting the disease's rarity (Vaz de Carvalho et al., PMC7164747, geoepidemiologic systematic review of individual patient data).

Sources: StatPearls, Orphanet, PMC3437607, PMC7164747

2. Etiology

Primary causal mechanism: Transplacental passage (via neonatal FcRn receptor) of maternal IgG anti-Ro/SSA (52-kDa and 60-kDa) and anti-La/SSB antibodies during the second and third trimesters, when IgG transport peaks. Anti-Ro (anti-SSA) is present in ~95% of affected infants' mothers (StatPearls). Anti-U1-RNP antibodies define a separate, generally cardiac-sparing NLE phenotype (NEJM 1987, classic description) — "The Neonatal Lupus Syndrome Associated with U1RNP (nRNP) Antibodies."

Risk factors: - Genetic (maternal): HLA-A1, HLA-B8, HLA-DR3, HLA-B15, HLA-C02, HLA-DQ5, HLA-DR10 increase risk of cardiac NLS; HLA-DRB104 and HLA-Cw05 confer susceptibility to anti-SSA/Ro-mediated congenital heart block (CHB), while HLA-DRB113 and HLA-Cw06 are protective (J Rheumatol 2025, PMID:38825356). - Genetic (fetal): HLA-DQB102, DRB103, and TNF-α promoter polymorphisms associate with milder (skin-limited) disease. - A recent multiethnic 2024 study found HLA-wide analyses did NOT identify robust NLE risk alleles, and broader SLE-associated genetic risk was not significantly associated with NLE outcomes — suggesting the field's earlier HLA associations may be less generalizable than thought (Lupus Foundation of America summary of J Rheumatol 2025 findings, PMID:38825356). - Obstetric/exposure: Prior affected pregnancy is the single strongest risk factor (recurrence risk 15–25% vs. <1–2% for first affected pregnancy); maternal antibody titer and epitope specificity (e.g., 52-kDa Ro/SSA epitopes preferentially recognized by mothers of CHB-affected children, PMC1526571). - Protective factor: Anti-β2-glycoprotein I antibodies have been reported to associate with reduced risk of anti-Ro60-associated cardiac NLE in some cohorts (ResearchGate/PubMed).

Gene–environment interaction: The central "interaction" is immunologic rather than classically environmental — maternal autoimmune serology (genetically influenced) combines with the developmental window of fetal cardiac conduction system remodeling (18–24 weeks gestation), when physiological apoptosis exposes normally intracellular Ro/La antigens on the cell surface, creating a narrow window of vulnerability to circulating maternal antibody.

Sources: J Rheumatol 2025 — Genetics of NLE Risk, PMC1526571, NEJM 1987 U1RNP

3. Phenotypes

Cardiac (most severe manifestation)

Congenital (complete) heart block (CHB): third-degree AV block is the "signature lesion" of cardiac NLE; second- and first-degree AV block also occur and may be reversible. Onset window: 18–24 weeks gestation (rarely later, and rarely postnatal, first-degree block). HP suggestion: HP:0001680 (Atrioventricular block) / HP:0011705 (Complete atrioventricular block).
Endocardial fibroelastosis, dilated cardiomyopathy: can present neonatally or emerge late (postnatal incidence 19–29% despite normal in-utero function) — HP:0001635 (dilated cardiomyopathy).
Valvular insufficiency, sinus node dysfunction, prolonged QTc.
Frequency: CHB occurs in 15–30% of NLE cases overall; regional variation is striking — ~70% of NLE cases in European/American cohorts present with CHB vs. only 8.9–23% in Asian cohorts, where cutaneous disease predominates (~80%) (PMC7164747, geoepidemiology review).

Cutaneous

Erythematous, annular/polycyclic photosensitive plaques, often with central scaling, classically periorbital ("raccoon-eye" appearance) and on the scalp/face — HP:0025426 (Photosensitivity) plus HPO annular erythema terms.
Onset: may be present at birth but frequently emerges within the first weeks of life (UV exposure–triggered); resolves over 6–12 months as maternal antibody clears, occasionally leaving telangiectasia, atrophy, or dyspigmentation.
Sex distribution paradox: cutaneous NLE shows a reported male predominance (2:1–3:1) in several series, contrasting with the strong female predominance of adult SLE (though at least one 57-case registry found female predominance — literature is mixed).

Hepatobiliary

Occurs in ~15–25% of cases: transaminitis, cholestasis, hepatomegaly/splenomegaly, and rarely a hemochromatosis-like or lupus-hepatitis picture with portal lymphocytic infiltration. Generally transient, resolving over months. HP: HP:0001392 (Abnormality of the liver), HP:0001396 (Cholestasis).

Hematologic

Occur in ~27% of infants: neutropenia, thrombocytopenia, hemolytic or non-hemolytic anemia, thought to arise from antibody binding to fetal blood cell antigens/immune complex-mediated peripheral destruction. HP: HP:0001873 (Thrombocytopenia), HP:0001875 (Neutropenia).

Neurological (underrecognized)

Benign, usually asymptomatic hydrocephalus/macrocephaly — prevalence ~8.0% in one cohort of 47 NLE infants vs. 0.048–0.081% in the general population. Also reported: white-matter abnormalities, basal ganglia calcification, intracranial hemorrhage, subependymal pseudocysts, seizures, myelopathy/spastic paraparesis (rare, symptomatic subset). Typically resolves without sequelae as antibody clears. HP: HP:0000238 (Hydrocephalus), HP:0000256 (Macrocephaly).

Quality of life / severity

Cutaneous, hepatic, and hematologic NLE are self-limited (4–12 months) with generally good QoL outcomes. Cardiac NLE is the dominant driver of morbidity/mortality and lifelong pacemaker dependence, with associated psychosocial and quality-of-life burden for families, though no NLE-specific EQ-5D/SF-36 instrument was located in the literature searched.

Sources: DermNet NZ, PMC7164747 geoepidemiology, PubMed 17330304 — hydrocephalus/macrocephaly, Nature Reviews Rheumatology

4. Genetic/Molecular Information

NLE has no primary causal germline mutation in the affected infant — it is antibody-mediated, not inherited in a Mendelian sense. Genetic contributions operate at the level of maternal (and modestly, fetal) susceptibility:

HLA associations (maternal): HLA-A1, B8, DR3, B15, C02, DQ5, DR10 (cardiac NLS risk); DRB104/Cw05 (susceptibility); DRB113/Cw06 (protective) (J Rheumatol, PMID:38825356).
Fetal modifiers: HLA-DQB102, DRB103, TNF-α promoter polymorphism — associated with milder/skin-limited disease.
Target autoantigens: Ro60 (TROVE2/SSA2, hgnc:11313), Ro52/TRIM21 (hgnc:11312), La/SSB (hgnc:10646), and in the U1RNP subset, U1-70K/SNRNP70 and other spliceosomal proteins.
No pathogenic germline variant classification (ACMG/AMP) applies — this is not a ClinVar-indexed Mendelian disorder. gnomAD/ClinVar searches are not informative here.
Epigenetics: Not a major described mechanism for NLE itself (distinguish from adult SLE, where DNA methylation changes in T cells are well described); no NLE-specific DiseaseMeth/ENCODE data were identified.
Chromosomal abnormalities: Not implicated; NLE is acquired/immune-mediated, not cytogenetic.

The 2025 J Rheumatol genetics paper is the most current authoritative source: broader SLE genetic-risk scores were not significantly associated with NLE outcome in a multiethnic mother-infant cohort, indicating the maternal antibody profile (not global SLE genetic burden) is the operative determinant.

Sources: J Rheumatol — Genetics of NLE, Lupus Foundation summary

5. Environmental Information

UV light is the principal recognized environmental trigger/exacerbant for the cutaneous phenotype — lesions are classically photo-distributed and can be precipitated or worsened by neonatal sun/phototherapy exposure.
No infectious agent is causally implicated; NLE is autoantibody-mediated, not infectious.
No specific maternal lifestyle factor (diet, smoking) has robust evidence as a risk/protective modifier in the literature reviewed; the dominant "environmental" exposure is the maternal autoantibody itself crossing the placenta during the critical fetal cardiac developmental window (18–24 weeks).

Source: DermNet NZ

6. Mechanism / Pathophysiology

Causal chain (cardiac NLE): 1. Trigger: Maternal anti-Ro60/anti-Ro52 (± anti-La) IgG crosses the placenta via FcRn transport, concentrating in fetal circulation during 2nd–3rd trimester. 2. Antigen exposure: During normal physiological remodeling of the fetal cardiac conduction system (weeks 18–24), cardiomyocytes undergo apoptosis, translocating normally intracellular Ro60/Ro52/La antigens to the cell surface in apoptotic blebs — a process requiring hY3 RNA for Ro60 surface exposure (PMC3708308). 3. Antibody binding — two complementary hypotheses: - Apoptosis hypothesis: Surface-bound anti-Ro/La antibodies impair the normal, non-inflammatory clearance of apoptotic cardiomyocytes by healthy neighboring myocytes, diverting clearance to macrophages, which release pro-inflammatory/pro-fibrotic cytokines. - Calcium-channel hypothesis: Molecular mimicry between Ro antigen and cardiac L-type and T-type (α1G) calcium channels — anti-Ro/La antibodies directly bind fetal cardiomyocyte calcium channels, disturbing calcium homeostasis (JEM, PMC2212767) and disrupting AV/SA nodal conduction independent of inflammation. 4. Fibrotic amplification: Anti-Ro60 binding triggers conformational activation of the uPA/uPAR system, generating plasmin, which activates TGF-β, driving a profibrotic cascade (PMID:22013113). 5. Downstream pathology: Progressive macrophage/giant-cell infiltration, fibrosis, and dystrophic calcification of the AV node → irreversible replacement of conduction tissue → third-degree AV block. This explains why steroid (anti-inflammatory) treatment can sometimes reverse early first/second-degree block but never reverses third-degree (complete) block, since fibrotic replacement is structural, not inflammatory. 6. Cutaneous/hepatic/hematologic mechanism: Parallel but reversible antibody-mediated cell injury/immune complex formation in skin (UV-potentiated keratinocyte apoptosis with Ro/La surface exposure), liver (portal lymphocytic infiltration), and blood cells (peripheral antibody-mediated destruction) — these resolve as maternal antibody is catabolized (half-life ~3 weeks, clearing by 6–12 months).

Suggested ontology terms: - GO: GO:0006915 (apoptotic process), GO:0035589 (G-protein coupled purinergic receptor... — N/A), GO:0007568 — better: GO:0030041 (actin filament...) — most relevant: GO:0043408 (regulation of MAPK cascade) is not central; use GO:0030512 (negative regulation of TGF-beta receptor signaling — inverse) → prefer GO:0007179 (transforming growth factor beta receptor signaling pathway, MODIFIER: INCREASED), GO:0006508 (proteolysis, for uPA/plasmin), GO:0005513 (detection of calcium ion), GO:0086012 (membrane depolarization during cardiac muscle cell action potential). - CL: CL:0000746 (cardiac muscle cell), CL:0000235 (macrophage), CL:0002496 (cardiac neuron / conduction-system cell — or CL:1000306 nodal myocyte if available). - UBERON: UBERON:0002018 (atrioventricular node). - CHEBI: relevant to hydroxychloroquine (CHEBI:5801) mechanistically, not a metabolite of the disease itself.

Sources: PMC3708308, JEM/PMC2212767, PMID:22013113 — uPA/TGF-β, PMC3467518, PMC11120786 — Molecular Mechanisms review

7. Anatomical Structures Affected

Organ level: Heart (primary, most severe), skin, liver/biliary tree, hematopoietic/blood, CNS (secondary). Body systems: cardiovascular, integumentary, hepatobiliary, hematologic, nervous.
Tissue/cell level: Cardiac conduction system myocytes (AV node specifically — UBERON:0002018), epidermal keratinocytes, hepatic portal tract lymphocytes, macrophages (CL:0000235), megakaryocytes/platelets, neutrophils.
Subcellular: Apoptotic membrane blebs (site of Ro/La surface translocation) — GO Cellular Component: GO:0097169 (nuclear membrane) is not right; more precisely the plasma membrane surface (GO:0005886) via apoptotic bleb formation.
Localization: AV node (UBERON:0002018) for CHB; periorbital/scalp/facial skin for cutaneous disease; liver (UBERON:0002107); no strong lateralization pattern reported.

8. Temporal Development

Onset: Cardiac manifestations onset in utero, virtually always between 18–24 weeks gestation (rarely as late as 30 weeks; postnatal-onset first-degree block is rare). Cutaneous/hepatic/hematologic manifestations are present at birth or emerge in the first weeks to months of postnatal life.
Progression: CHB, once complete (third-degree), is permanent and non-reversible; first/second-degree block may progress to complete block or, with steroid treatment, may partially regress (second→first degree). Cutaneous/hepatic/hematologic disease is self-limited, resolving over 4–12 months.
Disease course: Cardiac NLE is a chronic, lifelong condition once complete block is established (pacemaker-dependent); cutaneous/hepatic/hematologic NLE is self-limited/transient.
Critical window: Weeks 16–26 gestation is the critical surveillance period (serial fetal echocardiography); this is the therapeutic window for hydroxychloroquine initiation (before 10 weeks gestation) in the PATCH trial protocol.

9. Inheritance and Population

Inheritance pattern: Not Mendelian — acquired via transplacental antibody transfer. Recurrence in subsequent pregnancies is driven by persistent maternal antibody status, not classical genetic transmission.
Epidemiology:
Overall NLE incidence: ~1 in 20,000 US live births.
Among anti-SSA/anti-SSB-positive mothers: NLE incidence ~2% in a first at-risk pregnancy.
CHB specifically: 1–2% prevalence among anti-Ro-positive pregnant women; 15–30% of NLE cases have CHB overall (with strong regional variation: ~70% in Europe/US cohorts vs. 8.9–23% in Asian cohorts, where cutaneous disease predominates at ~80%).
Recurrence risk: <1% in mothers with a prior unaffected pregnancy; 15–25% (some sources cite up to 18–20%) if a prior child had NLE/CHB.
Mortality: Neonatal mortality for cardiac NLE is 20–30%; a large registry reported 11.8% overall mortality with median 7-year follow-up, 79.1% pacemaker rate, and 18.8% dilated cardiomyopathy rate.
Sex ratio: Overall NLE incidence shows no significant sex difference; cutaneous NLE specifically shows a reported (though inconsistently replicated) male predominance (2:1–3:1 in some series; female predominance in at least one 57-patient registry).
Geographic/ethnic distribution: Notable geoepidemiologic variation — European/American cohorts skew cardiac-predominant, Asian cohorts skew cutaneous-predominant, per systematic individual-patient-data review (PMC7164747). Non-European ancestry is also a reported risk factor for late-onset dilated cardiomyopathy in CHB survivors.

Sources: JACC — National Neonatal Lupus Registry, PMC7164747, PMC11899241

10. Diagnostics

Maternal serology: Anti-Ro/SSA (52-kDa and 60-kDa) and anti-La/SSB antibody testing (ELISA/immunoblot) — the essential first-line test in any pregnancy with suspected/known maternal autoimmune disease or an affected prior pregnancy.
Fetal cardiac surveillance: Serial fetal echocardiography with mechanical PR-interval (Doppler-derived AV time interval) measurement, weekly from 16–26 weeks gestation (some protocols 18–26 weeks) and biweekly 26–34 weeks, per PRIDE study and subsequent guidance. PR interval >150 ms = first-degree block; >140 ms triggers more frequent monitoring.
Postnatal: ECG/echocardiography for confirmation and grading of AV block; skin biopsy (interface dermatitis with vacuolar degeneration, lymphocytic infiltrate — similar to subacute cutaneous LE) if cutaneous diagnosis is uncertain; direct immunofluorescence may show granular IgG deposition at the dermo-epidermal junction.
Laboratory: CBC (cytopenias), liver function tests (transaminases, bilirubin), ANA/anti-Ro/anti-La titers in the infant (reflecting passive maternal transfer, not endogenous production).
Neuroimaging: Cranial ultrasound recommended in at-risk infants to screen for hydrocephalus/macrocephaly.
Differential diagnosis: Other causes of fetal bradycardia (structural heart disease, long QT syndrome), other neonatal photosensitive dermatoses (e.g., erythema multiforme, tinea), TORCH infections (for hepatosplenomegaly/cytopenias), other causes of cholestatic liver disease in infancy.
Screening: No population-based newborn screening program exists; screening is targeted — any mother with known anti-Ro/anti-La antibodies (with or without overt SLE/Sjögren's) should have anticipatory fetal cardiac and postnatal skin surveillance.

Sources: PRIDE study, PMID:18195175, Circulation — Utility of Cardiac Monitoring, ISUOG Congenital Heart Block

11. Outcome/Prognosis

Non-cardiac NLE: Excellent prognosis — cutaneous, hepatic, and hematologic manifestations are self-limited and typically resolve fully within 4–12 months without long-term sequelae (occasional residual dyspigmentation/atrophy in severe cutaneous cases).
Cardiac NLE:
Mortality: 20–30% for infants with complete heart block, concentrated in the neonatal/fetal period (hydrops, severe bradycardia, associated endocardial fibroelastosis/cardiomyopathy).
With timely pacemaker implantation, long-term survival exceeds 90%, and most survivors achieve normal neurodevelopment.
Dilated cardiomyopathy (DCM) is a major late complication: 10-year survival is only 23.1% for neonatally diagnosed DCM, 53.9% for late-onset DCM, vs. 98.6% for CHB infants without DCM.
Risk factors for late-onset DCM: non-European ancestry, in-utero mitral regurgitation, pacemaker implantation itself.
Pacemaker dependency is lifelong in nearly all complete-block survivors (79.1% pacemaker rate in a large registry).
Neurologic NLE: Generally resolves without sequelae once maternal antibody clears; symptomatic cases (seizures, myelopathy) are rare.
Prognostic biomarkers: Antibody titer/epitope specificity (52-kDa Ro reactivity), degree of AV block at presentation (reversible first/second-degree vs. irreversible third-degree), presence of endocardial fibroelastosis or in-utero valvular regurgitation.

Sources: ScienceDirect — long-term cardiac dysfunction, ScienceDirect — DCM incidence/mortality, PMC5578407

12. Treatment

Prenatal / preventive (targeting cardiac NLE): - Hydroxychloroquine (CHEBI:5801; NCIT drug class — Pharmacotherapy, NCIT:C15986): The PATCH trial (PMID:32674792) — 400 mg/day started before 10 weeks gestation, continued throughout pregnancy — showed recurrent CHB in only 1 of 17 completed hydroxychloroquine-exposed pregnancies (vs. historical recurrence rate ~18%), a >50% reduction. This is now the leading evidence-based secondary-prevention strategy for anti-Ro-positive mothers with a prior affected pregnancy. - Fluorinated corticosteroids (dexamethasone/betamethasone): Can reverse first- and second-degree block (inflammation-driven, pre-fibrotic stage) but have no effect on established third-degree (complete) block, since fibrotic replacement of the AV node is structurally irreversible. Carries maternal/fetal risk (growth restriction, oligohydramnios) — use is now more selective/controversial (PMID:10555029). - IVIG: A multicenter prospective observational study (PMID:20131278) at 400 mg/kg found IVIG ineffective for CHB prevention; higher-dose (1 g/kg) regimens have shown more promise in smaller/more recent studies (JACC: Clin EP 2022), but this remains investigational, not standard of care. - β-agonists (e.g., terbutaline, salbutamol): used adjunctively for severe fetal bradycardia to maintain ventricular rate in utero.

Postnatal: - Permanent pacemaker implantation (epicardial in neonates): definitive treatment for symptomatic/high-grade complete heart block — NCIT:C15329 (Surgical Procedure) / device-based; corresponds to therapeutic_modality: DEVICE. - Topical corticosteroids and photoprotection (sun avoidance, protective clothing/sunscreen): mainstay for cutaneous NLE, supportive/symptomatic; NCIT:C15747 (Supportive Care). - Supportive care for hepatic/hematologic disease: typically self-resolving; only symptomatic/severe cytopenias require transfusion support.

Experimental / future directions: - Investigation of immune checkpoint molecule dysregulation in autoimmune CHB (2024 research direction noted in search results) as a potential mechanistic/therapeutic target. - Belimumab, rituximab, and other B-cell-targeted therapies have been explored in maternal SLE management around pregnancy but are not established NLE-preventive agents.

NCIT term suggestions: NCIT:C15986 (Pharmacotherapy, for hydroxychloroquine/steroids with therapeutic_agent CHEBI:5801 hydroxychloroquine), NCIT:C15329 (Surgical Procedure, pacemaker), NCIT:C15747 (Supportive Care).

Sources: PATCH trial JACC, PMC7394202, Pisoni IVIG study, JACC Clin EP 2022 — high-dose IVIG

13. Prevention

Primary prevention: Pre-conception counseling/screening for anti-Ro/anti-La antibodies in women with known or suspected autoimmune disease (SLE, Sjögren's) planning pregnancy; the 2024 Bankole & Nwaonu review explicitly recommends NLS-antibody screening occur before pregnancy as a collaborative rheumatology-obstetrics practice.
Secondary prevention: Hydroxychloroquine for anti-Ro/La-positive women, particularly those with a prior affected pregnancy (per PATCH trial protocol, started pre-10 weeks gestation).
Screening/early detection: Serial fetal echocardiography (mechanical PR interval) from 16–26 weeks gestation in all anti-Ro/anti-La-positive pregnancies, enabling detection of early (reversible) AV block before progression to complete block.
Genetic counseling: Not classical Mendelian counseling (no causal fetal genotype), but risk counseling on recurrence rates (15–25% after one affected pregnancy) is standard practice for affected families.
No vaccine or population-level public health intervention applies (not infectious/environmental in a classical sense).

Sources: SAGE review 2024 (Bankole & Nwaonu), PMC6099126 — provider practice survey

14. Other Species / Natural Disease

No robust literature was identified describing naturally occurring NLE-like disease in companion animals or wildlife (OMIA search did not surface a canine/feline analog in this research pass). This is consistent with NLE being a human-specific, antibody/placenta-mediated acquired condition tied to human IgG transplacental transport physiology (FcRn-mediated) and human Ro/La antigen epitopes.

15. Model Organisms

Passive-transfer murine models: IgG purified from anti-Ro/La-positive mothers (or affinity-purified anti-Ro60/anti-Ro52 antibodies) injected into pregnant mice have been used to study antibody-mediated cardiac conduction abnormalities, supporting both the apoptosis and calcium-channel hypotheses (e.g., work underlying PMC2212767, Ro/SSA autoantibodies directly bind cardiomyocytes, JEM 2005).
In vitro/ex vivo models: Cultured human fetal cardiomyocytes and keratinocytes have been central to demonstrating apoptosis-induced surface translocation of Ro60/La and the requirement for hY3 RNA (PMC3708308); isolated perfused fetal/neonatal heart preparations have been used to test T-type calcium channel (Cav3.1/α1G) blockade by anti-Ro antibodies (PMC3767782).
Limitations: Mouse models lack a direct anatomic/physiologic analog of the human fetal AV nodal remodeling window and human-specific Ro52/TRIM21 antigenicity, so translational fidelity for the exact CHB timing (18–24 weeks in humans) is imperfect — an appropriate HUMAN_MODEL_MISMATCH candidate for dismech curation, since these models demonstrate antibody-calcium channel/apoptosis interactions but do not fully recapitulate the human developmental timing or AV-node-specific fibrotic outcome.
General lupus mouse models (e.g., MRL/lpr) are relevant to maternal SLE pathogenesis broadly but are not NLE-specific models.

Sources: PMC3708308, Wiley — Role of Calcium Channels in CHB, PMC3767782

Summary Table: Suggested Ontology Bindings for Curation

Table (click to expand)

Concept	Suggested Term
Disease	MONDO:0018360; ORPHA:398124
Complete heart block	HP:0011705
First-degree AV block	HP:0011706 (or general HP:0001680)
Dilated cardiomyopathy	HP:0001635
Photosensitive annular rash	HP:0025426 + skin lesion terms
Hydrocephalus	HP:0000238
Macrocephaly	HP:0000256
Thrombocytopenia	HP:0001873
Neutropenia	HP:0001875
Cholestasis	HP:0001396
Ro60 antigen gene	hgnc:11313 (TROVE2)
Ro52/TRIM21 gene	hgnc:11312 (TRIM21)
La/SSB gene	hgnc:10646 (SSB)
AV node	UBERON:0002018
Macrophage	CL:0000235
Cardiac muscle cell	CL:0000746
Apoptotic process	GO:0006915
TGF-beta signaling	GO:0007179 (modifier: INCREASED)
Hydroxychloroquine	CHEBI:5801
Pharmacotherapy	NCIT:C15986
Surgical procedure (pacemaker)	NCIT:C15329

Full Source List

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Table (click to expand)

Outcome	Count
References checked	36
Resolved	35
Unresolved (possible confabulation)	0
Unverifiable	1
Quoted claims checked	1
Quoted claims found in source	0
Quoted claims not found in source	1
References weighed for topical relevance	35
On topic	26
Off topic	0

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

PMC:PMC3437607 (abstract only): "an example of passively acquired autoimmunity in which the influx of maternal autoantibodies... transiently affects fetal and neonatal organ systems"
closest text in source: "Neonatal lupus erythematosus (NLE) refers to a clinical spectrum of cutaneous, cardiac, and systemic abnormalities observed in newborn infants whose mothers have autoantibodies against Ro/SSA and La/SSB"